Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).

Date publication

juillet 2018

Journal

The American journal of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BARDOU Marc , Pr QUANTIN Catherine

Tous les auteurs :
Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, Quantin C, Bardou M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29961771

Résumé

Inflammatory bowel diseases (IBD) need long-term treatment, which can influence pregnancies in young women. Uncontrolled IBD is associated with poor pregnancy outcomes. Despite the labeling of Anti-tumor necrosis factor (TNF) antibodies (anti-TNFα) which indicates that their use is not recommended during pregnancy, anti-TNFα are increasingly being used during pregnancy and may expose women and their fetuses to treatment-related complications. Existing recommendations on the timing of treatment during pregnancy are inconsistent. We aimed to assess the safety of anti-TNFα treatment in pregnant women with IBD, and up to the first year of life for their children.

Référence

Am. J. Gastroenterol.. 2018 Jul 2;: